Pauline Gee

Biography

Pauline was awarded the 2005 PolyPops Foundation Award for innovative applications in the area of microplate development and design by the Society of Biomolecular Sciences. Previously, Pauline was Chief Technology Officer at Sciona, Inc., where she led the Company to regulatory compliance in genetic testing. At CeMines, Inc., Pauline was responsible for commercializing protein biomarkers for early detection of cancer as Vice-President and General Manager. At MDS Pharma Services, Pauline led the Company's chemogenomics and toxicogenomics efforts, representing MDS Pharma Services as Vice-President of Predictive Biology in its alliance with Iconix Pharmaceuticals. Before joining MDS Pharma Services, Pauline was President and CEO of Xenometrix, Inc., a public company that pioneered gene expression profiling to describe cellular responses to compounds and developed HTS Ames testing for mutagenicity. She brought Xenometrix to profitability which won Deloitte and Touchè Fast 50 Awards for two years before merging the company with Discovery Partners International, Inc. Pauline earned a doctorate in neurochemistry and B.S. degree in biology from Simon Fraser University, in British Columbia, Canada. As a Medical Research Council Fellow, she analyzed oxidized DNA bases and developed and patented DNA base-specific Ames strains at the University of California Berkeley. She was the first to demonstrate DNA repair in differentiated neurons at Stanford University.

Research Interest

DNA repair in differentiated neurons